Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

ivate Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: challenges, risks and costs inherent in business integrations and in achieving anticipated synergies; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; the impacts of competition; changes in economic and financial conditions of the company's business; uncertainties and matters beyond the control of management; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, the providing of estimates of financial measures, in accordance with GAAP and related standards. These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by the company or by persons acting on its behalf and in conjunction with its periodic SEC filings. In addition, please refer to the cautionary statements and risk factors set forth in the company's Report on Form 10-Q, for the period ended June 30, 2011, and in its other filings with the SEC. Further, uncertainties or other circumstances, or matters outside of the company's control between the date of this release and the date that its Form 10-Q for the quarter ended September 30, 2011, is filed with the SEC could potentially result in adjustments to reported results. The company undertakes no obligation to update statements herein for revisions or changes after the date of this release.

Mylan Inc. and SubsidiariesCondensed Consolidated Statements of Operations(Unaudited; in thousands, except per share amounts)Three Months Ended September 30,Nine Months End
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Life Technologies Announces Third Quarter 2011 Results
3. Insmed to Host 2011 Third Quarter Earnings Conference Call
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
8. HeartWare Schedules Third Quarter Conference Call and Webcast
9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... CO (PRWEB) August 27, 2014 Flagship ... analysis services to the pharmaceutical and medical device ... expansion. The fast growing company has consolidated its ... Aurora and Boulder to Westminster, CO, just north of ... Histology Lab, 7575 W. 103rd Ave., Suite 100, Westminster, ...
(Date:8/27/2014)... , Aug. 27, 2014 Tris Pharma, ... delivery technologies, today announced that it has been selected ... & Industry Association,s 2014 Awards for Excellence ... by an independent panel of judges from SCORE (Counselors ... Award winners will be honored at a gala event ...
(Date:8/27/2014)... 2014 According to the 2013 Raw ... the look and feel of markets for raw materials ... ingredients will push for more branded, science-backed products.” , ... strong market growth in the last decade as consumers ... and cosmetics to fit a more ‘wellness’ lifestyle approach. ...
(Date:8/26/2014)... Scientists have developed what they believe is the ... made in sheets only three atoms thick. , ... two of these single-layer semiconductor materials can be ... a heterojunction. This result could be the basis ... diodes, or LEDs, and solar technologies. , "Heterojunctions ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2
... SUNNYVALE, Calif., Nov. 13 Voler,( http://www.volersystems.com ) ... design capabilities beyond prototypes and custom test,systems to ... human use.,"Voler continues to invest in upgrades to ... our multidisciplinary team," stated Walt Maclay,president of Voler. ...
... Future Healthcare and Education, OLDSMAR, Fla., Nov. ... largest and most established private,cord blood banks and ... agreement as an exclusive retailer with Upromise(R) the,largest ... Since,2004, Cryo-Cell has been the only cord blood ...
... Requires Only Weekly Dosing, SAN DIEGO, Nov. ... trial data demonstrating that ARX201, the company,s,long-acting human ... Serono, normalized insulin-like growth factor I (IGF-I) levels,while ... adults,with Growth Hormone deficiency. The results of this ...
Cached Biology Technology:Voler Expands Medical Device Design Capabilities 2Voler Expands Medical Device Design Capabilities 3Cryo-Cell Renews Upromise Industry-Exclusive Agreement 2Cryo-Cell Renews Upromise Industry-Exclusive Agreement 3Cryo-Cell Renews Upromise Industry-Exclusive Agreement 4Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated 2Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated 3
(Date:8/27/2014)... Gamblers are greedy bird-brains, University of Warwick research finds ... when they make risky decisions, new research has shown. ... University of Warwick,s Department of Psychology, conducted tests that ... more likely to gamble for high-value than low-value rewards. ... argue that the test results show the important role ...
(Date:8/26/2014)... have developed algorithms to identify weak spots in tendons, ... technology, which needs to be refined before it is ... strains and tiny injuries in the body,s tissues long ... online Aug. 27 in the Journal of the ... nexus of the physical and life sciences. , "Tendons ...
(Date:8/26/2014)... the University of Warwick have provided the first ... protein is linked to early signs of dementia. ... research found that the absence of the protein ... in the nervous system. These changes were shown ... of dementia, including restricted learning and memory formation ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Lack of naturally occuring protein linked to dementia 2
... FRANCISCOSatellite observations have revealed the first direct evidence of ... sheet, tarnishing the ice with soot and making it ... the American Geophysical Union meeting this week, an Ohio ... and Infrared Pathfinder Satellite Observation (CALIPSO) satellite, which captured ...
... most powerful X-ray laser, has revealed the three dimensional structure ... causes African trypanosomiasis (or sleeping sickness) in humans. ... cathepsin B enzyme, it will be possible to design new ... causes sleeping sickness, leaving the infected human unharmed. The ...
... recent University of Colorado Cancer Center review in the journal ... promising cancer prevention properties. Meanwhile, an ongoing clinical trial is ... of colon cancer. "While I have been trained ... to deliver bioactive, cancer fighting compounds with food, and this ...
Cached Biology News:Fire and ice: Wildfires darkening Greenland snowpack, increasing melting 2X-ray laser helps slay parasite that causes sleeping sickness 2Clinical trial tests rice bran to prevent cancer 2
... This goat anti-rabbit IgG FITC ... antibody' for immunofluorescent staining on tissues ... antibody is generated in rabbits. It ... controls, such as omitting the primary ...
1000X solution used for inducing CopyControl™ based vectors to high copy numbers...
Request Info...
HAS1 (C-14)...
Biology Products: